Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/27/2026, 10:25:37 AM
Content snapshot
{ "session_id": "sess-hyp-1b87d283fc0c", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "llm", "action": "synthesize", "content": "\n\n# Synthesis: TREM2 Microglial Activation for Amyloid Clearance in Alzheimer's Disease\n\n## Dimension Scores\n\n| Dimension | Score | Rationale |\n|-----------|-------|-----------|\n| **Mechanistic Plausibility** | 0.88 | R47H variant provides strong loss-of-function evidence; SYK/PLCγ2/CARD9 cascade is well-defined; connects microglial dysfunction to amyloid pathology |\n| **Evidence Strength** | 0.68 | Human genetics is compelling, but preclinical-to-clinical translation remains incomplete; biphasic pharmacology complicates interpretation; model validity questions persist |\n| **Novelty** | 0.70 | Agonistic antibody approach represents meaningful innovation beyond loss-of-function genetics; multiple candidates (AL002c, 4D9) in development |\n| **Feasibility** | 0.58 | Receptor is druggable via antibodies, but biphasic dose-response creates narrow therapeutic window; timing uncertainty and patient stratification needs add complexity |\n| **Therapeutic Potential** | 0.74 | Addressable genetic risk is high; mechanism targets upstream pathology; but narrow window and individual variability may limit broad efficacy |\n\n---\n\n## Integrated Analysis\n\n### Strongest Arguments (Pro-Hypothesis)\n\n1. **Genetic architecture is exceptional.** The R47H variant provides ~3-fold increased AD risk with clear loss-of-function mechanism—the most direct human validation linking microglial dysfunction to Alzheimer's pathogenesis. This is a rare \"druggable genetic\" context where the variant unambiguously implicates the target.\n\n2. **Mechanistic coherence.** The signaling cascade (SYK → PLCγ2 → CARD9) is molecularly resolved, enabling pathway-specific drug design and biomarker development.\n\n3. **Plaque phenotypes are reproducible.** Mouse model data consistently shows microglial chemotaxis toward amyloid deposits and improved plaque compaction with T", "tokens_used": "462", "persona_id": "persona-synthesizer" }